Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response

This is a multicenter, randomized, double‐blind, placebo‐controlled Phase III study withan open‐label extension. The purpose is to evaluate efficacy and safety in adult patientswith chronic hepatitis B virus infection who have received at least 12 months of NAstherapy, to demonstrate that TQA3605 Tablets combined with oral nucleos(t)ide analoguescan improve efficacy with satisfactory safety profile compared with oral nucleos(t)ideanalogues alone in this population. Approximately 930 adult patients with chronichepatitis B virus infection who have received at least 12 months of NAs therapy areplanned to be enrolled in this study.